Proprietary CDMS platform — from eCRF to statistical analysis.

Explore · 72%

Our French specialist in clinical biometrics & data management — and the cornerstone of the Oxurion platform.

Oxurion/Investors/News/Oxurion NV Announces First Patient Dosed in its Phase 2 S…

Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

13 Oct 2021General

Oxurion (Euronext Brussels: OXUR) is a Belgian company building a leading European group of clinical research organizations.

OXUR · EURONEXT BRUSSELS€0.0034

0.00%·3 Jun 2026

Oxurion NV
Gaston Geenslaan 1
B-3001 Leuven
Belgium

info@oxurion.com
+32 16 75 13 10